Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 11, 2015, Pages 3150-3158

  Maura, Francesco ^a   Cutrona, Giovanna ^b   Mosca, Laura ^a   Matis, Serena ^b   Lionetti, Marta ^a   Fabris, Sonia ^a   Agnelli, Luca ^a   Colombo, Monica ^b   Massucco, Carlotta ^b   Ferracin, Manuela ^c   Zagatti, Barbara ^c   Reverberi, Daniele ^b   Gentile, Massimo ^d   Recchia, Anna Grazia ^d   Bossio, Sabrina ^d   Rossi, Davide ^e   Gaidano, Gianluca ^e   Molica, Stefano ^f   Cortelezzi, Agostino ^a   Di Raimondo, Francesco ^g   Negrini, Massimo ^c   Tassone, Pierfrancesco ^h   Morabito, Fortunato ^d   Ferrarini, Manlio ^b   Neri, Antonino ^a   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d Azienda Ospedaliera di Cosenza   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f PUGLIESE CIACCIO HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

B cell receptor; BCL2; chronic lymphocytic leukemia; gene expression profiling; microRNA; stereotyped VH CDR

Indexed keywords

B LYMPHOCYTE RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN HEAVY CHAIN VARIABLE PROTEIN; MF2A PROTEIN; MICRORNA; MICRORNA 29C; MICRORNA 497; NOTCH1 RECEPTOR; PDGFA PROTEIN; PROTEIN; PROTEIN BCL 2; SF3B1 PROTEIN; TFEC PROTEIN; UNCLASSIFIED DRUG; WDFY4 PROTEIN; COMPLEMENTARITY DETERMINING REGION; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE ANTIGEN RECEPTOR; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; UPREGULATION; B LYMPHOCYTE; BIOLOGY; CLINICAL TRIAL; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MUTATION; REPRODUCIBILITY;

AGED; B-LYMPHOCYTE SUBSETS; CLUSTER ANALYSIS; COMPLEMENTARITY DETERMINING REGIONS; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICRORNAS; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; RECEPTOR, NOTCH1; RECEPTORS, ANTIGEN, B-CELL; REPRODUCIBILITY OF RESULTS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; TRANSCRIPTOME;

EID: 84947813967     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1028051     Document Type: Article

References (45)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117: 1781-1791.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
4. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
5. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-1525.
6. Bomben R, Dal BM, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009; 144: 492-506.
7. Maura F, Cutrona G, Fabris S, et al. Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 2011; 6: e24313.
8. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111: 1524-1533.
9. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol 2014; 1 (2): e74-84.
10. Athanasiadou A, Stamatopoulos K, Gaitatzi M, et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 2008; 93: 473-474.
11. Kostareli E, Hadzidimitriou A, Stavroyianni N, et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009; 23: 919-924.
12. Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with stereotyped IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica 2010; 95: 1519-1525.
13. Marincevic M, Mansouri M, Kanduri M, et al. Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B cell receptors. Haematologica 2010; 95: 2072-2079.
14. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109: 259-270.
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
16. Rai KR, Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 1990; 4: 447-456.
17. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
18. Morabito F, Mosca L, Cutrona G, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res 2013; 19: 5890-5900.
19. Fabris S, Mosca L, Cutrona G, et al. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol 2013; 88: 24-31.
20. Morabito F, Cutrona G, Gentile M, et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009; 146: 44-53.
21. Fabris S, Mosca L, Todoerti K, et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2008; 47: 781-793.
22. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
23. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
24. Negrini M, Cutrona G, Bassi C, et al. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin Cancer Res 2014; 20: 4141-4153.
25. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114: e20-e26.
26. Zupo S, Massara R, Dono M, et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000; 95: 1199-1206.
27. Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17: 1722-1730.
28. Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391.
29. Yadav S, Pandey A, Shukla A, et al. miR-497 and miR-302b regulate ethanol-induced neuronal cell death through BCL2 protein and cyclin D2. J Biol Chem 2011; 286: 37347-37357.
30. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009; 15: 4415-4422.
31. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013; 27: 2196-2199.
32. Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010; 116: 2984-2993.
33. Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29: 3474-3482.
34. Zhao H, Yang W, Qiu R, et al. An intronic variant associated with systemic lupus erythematosus changes the binding affinity of Yinyang1 to downregulate WDFY4. Genes Immun 2012; 13: 536-542.
35. Gilling CE, Mittal AK, Chaturvedi NK, et al. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. Br J Haematol 2012; 158: 216-231.
36. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760.
37. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
38. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 2013; 19: 115-123.
39. Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenias in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116 (23): 4771-4776
40. Maura F, Visco C, Falisi E, et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 2013; 88: 32-36.
41. Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012; 18: 1870-1878.
42. Finnerty JR, Wang WX, Hebert SS, et al. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol 2010; 402: 491-509.
43. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
44. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-5171.
45. Ouillette P, Erba H, Kujawski L, et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008; 68: 1012-1021.